Novartis Purchase Of Chiron Puts Spotlight On Biologics
By Bailey Somers ( November 1, 2005, 12:00 AM EST) -- Drug maker Novartis AG's acquisition of Chiron Corp. will expand the Swiss company's footprints in the U.S. biotech market even as its generics division braces for a battle to launch the first generic biotech drugs in the United States....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.